Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
HLA Laboratory, |
RCV001788486 | SCV001712130 | association | Interstitial lung disease 2 | 2021-05-04 | no assertion criteria provided | case-control | |
HLA Laboratory, |
RCV001788487 | SCV001712135 | uncertain significance | Chronic obstructive pulmonary disease | 2021-05-04 | no assertion criteria provided | case-control | |
HLA Laboratory, |
RCV002472379 | SCV001749003 | uncertain significance | Combined pulmonary fibrosis-emphysema syndrome | 2021-05-04 | no assertion criteria provided | case-control | |
HLA Laboratory, |
RCV004995925 | SCV005044898 | uncertain significance | Susceptibility to severe coronavirus disease (COVID-19) | 2024-05-13 | no assertion criteria provided | research | The NC_000011.10:g.1291476C>G (rs111521887) is an intron variant in TOLLIP (toll interacting protein) that has been associated with idiopathic pulmonary fibrosis and other lung diseases. We evaluated this variant in 923 patients with COVID-19 and we did not find any association with mortality or severity risk. Due to the lack of association of the variant with the studied phenotypes, it was classified as uncertain significance. |